Patents by Inventor Thorsten Ross
Thorsten Ross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12173422Abstract: The present invention refers to an electroplating composition for plating a chromium coating on a substrate, the composition comprising: (i) a source of hexavalent chromium; (ii) one or more than one betaine comprising a quaternary nitrogen and/or salts thereof; and (iii) one or more than one poly-organosiloxane.Type: GrantFiled: December 17, 2021Date of Patent: December 24, 2024Assignee: Atotech Deutschland GmbH & Co. KGInventors: Simon Pape, Oleksandra Yevtushenko, Anke Walter, Thorsten Ross
-
Publication number: 20240417475Abstract: The present invention relates to a bispecific antibody construct comprising (a) a first binding domain (A), which is capable of specifically binding to a first target (A) that is CD16A on the surface of an immune effector cell, wherein the first binding domain comprises: (i) a VL region comprising CDR-L1 as depicted in SEQ ID NO: 4, a CDR-L2 as depicted in SEQ ID NO: 5, and a CDR-L3 as depicted in SEQ ID NO: 6; and (ii) a VH region as depicted in SEQ ID NO: 7; and (b) a second binding domain (B), which is capable of specifically binding to a second target (B?) that is an antigen on the surface of a target cell, wherein the second target (B?) is FOLR1. The present invention also relates to related nucleic acid molecules, vectors, host cells, methods of producing the antibody constructs, pharmaceutical compositions, medical uses, and kits.Type: ApplicationFiled: November 3, 2022Publication date: December 19, 2024Inventors: Joachim KOCH, Jens PAHL, Thorsten ROSS, Jana-Julia SIEGLER, Holger DULAT
-
Publication number: 20240410071Abstract: The present invention relates to a method for depositing a chromium layer on a surface. The present invention relates in particular to a method for depositing a chromium layer on a surface of a round-shaped substrate, the method comprising a pre-treating step with a laser such that material is removed from the substrate.Type: ApplicationFiled: September 16, 2022Publication date: December 12, 2024Applicant: Atotech Deutschland GmbH & Co. KGInventors: Thorsten ROSS, Michael NORTHINGTON
-
Publication number: 20240294647Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: April 17, 2024Publication date: September 5, 2024Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Publication number: 20240035183Abstract: The present invention refers to an electroplating composition for plating a chromium coating on a substrate, the composition comprising: (i) a source of hexavalent chromium; (ii) one or more than one betaine comprising a quaternary nitrogen and/or salts thereof; and (iii) one or more than one poly-organosiloxane.Type: ApplicationFiled: December 17, 2021Publication date: February 1, 2024Applicant: Atotech Deutschland GmbH & Co. KGInventors: Simon PAPE, Oleksandra YEVTUSHENKO, Anke WALTER, Thorsten ROSS
-
Publication number: 20230365709Abstract: The present invention relates to a trispecific antibody construct comprising (i.) a first binding domain (A), which is capable of specifically binding to a first target (A?) that is CD16A on the surface of an immune effector cell; (ii.) a second binding domain (B), which is capable of specifically binding to a second target (B?) that is another antigen on the surface of an immune effector cell, wherein said antigen is selected from the group comprising CD56, NKG2A, NKG2D, NKp30, NKp44, NKp46, NKp80, DNAM-1, SLAMF7, OX40, CD47/SIRP?, CD89, CD96, CD137, CD160, TIGIT, nectin-4, PD-1, PD-L1, LAG-3, CTLA-4, TIM-3, KIR2DL1-5, KIR3DL1-3, KIR2DS1-5 and CD3; and (iii.) a third binding domain (C), which is capable of specifically binding to a third target (C?) that is an antigen on the surface of a target cell. The present invention also relates to related nucleic acid molecules, vectors, host cells, methods of producing the antibody constructs, pharmaceutical compositions, medical uses, and kits.Type: ApplicationFiled: October 8, 2021Publication date: November 16, 2023Inventors: Thorsten ROSS, Joachim KOCH, Michael TESAR, Holger DULAT, Christian BREUNIG, Eike PETERS, Kristina ELLWANGER, Ivica FUCEK, Uwe REUSCH, Jens PAHL
-
Patent number: 11572415Abstract: The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS. 1 and 2).Type: GrantFiled: April 11, 2018Date of Patent: February 7, 2023Assignee: AFFIMED GMBHInventors: Kristina Ellwanger, Ivica Fucek, Thorsten Ross, Thomas Mueller, Erich Rajkovic, Uwe Reusch, Martin Treder, Michael Weichel
-
Patent number: 11535672Abstract: The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.Type: GrantFiled: July 24, 2019Date of Patent: December 27, 2022Assignee: AFFIMED GMBHInventors: Joachim Koch, Martin Treder, Jens Pahl, Uwe Reusch, Thorsten Ross, Erich Rajkovic, Adelheid Cerwenka
-
Publication number: 20220041717Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCMType: ApplicationFiled: October 26, 2021Publication date: February 10, 2022Inventors: Thorsten ROSS, Ivica FUCEK, Kristina ELLWANGER, Michael WEICHEL, Uwe REUSCH, Stefan KNACKMUSS, Erich RAJKOVIC, Martin TREDER
-
Patent number: 11180558Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.Type: GrantFiled: July 23, 2019Date of Patent: November 23, 2021Assignee: Affimed GMBHInventors: Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch, Stefan Knackmuss, Erich Rajkovic, Martin Treder
-
Publication number: 20210253698Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: April 20, 2021Publication date: August 19, 2021Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Patent number: 11001633Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: GrantFiled: December 13, 2019Date of Patent: May 11, 2021Assignee: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Publication number: 20200109202Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: December 13, 2019Publication date: April 9, 2020Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Publication number: 20200010547Abstract: The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.Type: ApplicationFiled: July 24, 2019Publication date: January 9, 2020Inventors: Joachim Koch, Martin Treder, Jens Pahl, Uwe Reusch, Thorsten Ross, Erich Rajkovic, Adelheid Cerwenka
-
Publication number: 20190345249Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCMType: ApplicationFiled: July 23, 2019Publication date: November 14, 2019Inventors: Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch, Stefan Knackmuss, Erich Rajkovic, Martin Treder
-
Publication number: 20190040155Abstract: The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS. 1 and 2).Type: ApplicationFiled: April 11, 2018Publication date: February 7, 2019Inventors: Kristina ELLWANGER, Ivica FUCEK, Thorsten ROSS, Thomas MUELLER, Erich RAJKOVIC, Uwe REUSCH, Martin TREDER, Michael WEICHEL
-
Patent number: 7074315Abstract: In the production of printed circuit boards it is required that organic protective coatings adhere tightly on the copper surfaces. Accordingly, matt layers of copper are to be preferred over lustrous coatings. The bath in accordance with the invention serves to deposit matt layers of copper and has the additional advantageous property that the layers may also be deposited with sufficient coating thickness in very narrow bore holes at average cathode current density. For this purpose the bath contains at least one polyglycerin compound selected from the group comprising poly(1,2,3-propantriol), poly(2,3-epoxy-1-propanol) and derivatives thereof.Type: GrantFiled: October 10, 2001Date of Patent: July 11, 2006Assignee: Atotech Deutschland GmbHInventors: Gonzalo Urrutia Desmaison, Stefan Kretschmer, Gerd Senge, Thorsten Ross, Torsten Küssner
-
Publication number: 20040020783Abstract: In the production of printed circuit boards it is required that organic protective coatings adhere tightly on the copper surfaces. Accordingly, matt layers of copper are to be preferred over lustrous coatings. The bath in accordance with the invention serves to deposit matt layers of copper and has the additional advantageous property that the layers may also be deposited with sufficient coating thickness in very narrow bore holes at average cathode current density. For this purpose the bath contains at least one polyglycerin compound selected from the group comprising poly(1,2,3-propantriol), poly(2,3-epoxy-1-propanol) and derivatives thereof.Type: ApplicationFiled: April 7, 2003Publication date: February 5, 2004Inventors: Gonzalo Urrutia Desmaison, Stefan Kretschmer, Gerd Senge, Thorsten Ross, Torsten Kussner